VTX2735
Phase 2Small molecule
VTX2735 is one of 19 small molecule programs targeting Pericarditis. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Pericarditis
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Epidiolex
Jazz PharmaceuticalsApproved
Plaquenil
Alnylam PharmaceuticalsPhase 3
Rayos
RRoxane Laboratories
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
RPH-104
UUnknown Sponsor
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 2
Spikevax
ModernaPreclinical
High Dose Rifampicin
UUniversity of Cape Town
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VTX2735. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZomagen Biosciences Ltd.